慢性HBV感染免疫治疗的研究进展
Immunotherapy for Chronic Hepatitis B Virus Infection
DOI: 10.12677/PI.2019.83013, PDF,   
作者: 巫 涛, 黄 松, 刘 煜*：中国药科大学生命科学与技术学院，江苏 南京
关键词: 慢性乙型肝炎；免疫治疗；病理机制；研究进展；Chronic Hepatitis B； Immunotherapy； Immunopathogenesis； Research Progress
摘要: 慢性乙型肝炎病毒感染是一个全球性的公共卫生问题。近年来，丙型肝炎治疗药物取得突破，90%以上丙肝病人在使用新型药物后实现临床治愈，而慢性乙型肝炎的临床抗病毒治疗却依然依赖于干扰素和核苷(酸)类似物，这些药物难以彻底清除HBV。研究表明，慢性乙型肝炎的病理机制与宿主的抗病毒免疫应答有关，免疫系统在抑制和清除HBV方面发挥着重要作用。因此借助免疫系统治疗慢性乙型肝炎或可以抑制疾病发展，甚至治愈乙肝。本文总结了慢性乙型肝炎的病理机制，并对针对固有免疫和适应性免疫开发的药物和治疗方法进行总结，探讨了免疫治疗出现的挑战及应对方法。
Abstract: Chronic hepatitis B virus infection is a global public health problem. In recent years, hepatitis C treatment drugs have emerged, more than 90% of patients achieve clinical cure, while clinical treatment of chronic hepatitis B still depends on interferon and nucleot(s)ide analogues, but neither is able to achieve functional cure, because they can’t completely eliminate cccDNA. Many re-searches show that the pathological mechanism of chronic hepatitis B is related to the host’s antiviral immune response, and the immune system plays an important role in inhibiting HBV replication and clearing HBV. Therefore, reactivating the immune system may inhibit the development of chronic hepatitis B and even cure chronic hepatitis B. This article summarizes the pathological mechanism of chronic hepatitis B, immune treatments for innate and adaptive immunity, and the challenges and countermeasures of CHB immunotherapy.
文章引用：巫涛, 黄松, 刘煜. 慢性HBV感染免疫治疗的研究进展[J]. 药物资讯, 2019, 8(3): 105-112. https://doi.org/10.12677/PI.2019.83013

参考文献

[1] World Health Organization (2015) Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. World Health Organization.
[2] 刘求明, 尧晨光, 郭晓红, 等. 抗乙肝病毒药物研究新进展[J]. 病毒学报, 2016, 32(5): 650-658.
[3] Michel, M.-L. (2002) Towards Immunotherapy for Chronic Hepatitis B Virus Infec-tions. Vaccine, 20, A83-A88. [Google Scholar] [CrossRef] 
[4] Webster, G.J.M., Reignat, S., Maini, M.K., et al. (2010) In-cubation Phase of Acute Hepatitis B in Man: Dynamic of Cellular Immune Mechanisms. Hepatology, 32, 1117-1124. [Google Scholar] [CrossRef] [PubMed]
[5] Guidotti, L.G., Ishikawa, T., Hobbs, M.V., et al. (1996) Intracellular Inactivation of the Hepatitis B Virus by Cytotoxic T Lymphocytes. Immunity, 4, 25-36. [Google Scholar] [CrossRef] 
[6] Kruse, R.L., Shum, T., Legras, X., et al. (2017) In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy. Molecular Therapy. Methods & Clinical Development, 7, 32-41. [Google Scholar] [CrossRef] [PubMed]
[7] Matloubian, M., Concepcion, R.J. and Ahmed, R. (1994) CD4+ T Cells Are Required to Sustain CD8+ Cytotoxic T-Cell Responses during Chronic Viral Infection. Journal of Virology, 68, 8056-8063.
[8] Franzese, O., Kennedy, P.T.F., Gehring, A.J., et al. (2005) Modulation of the CD8+-T-Cell Response by CD4+ CD25+ Regulatory T Cells in Patients with Hepatitis B Virus Infection. Journal of Virology, 79, 3322-3328. [Google Scholar] [CrossRef] 
[9] Bertoletti, A. and Bert, N.L. (2018) Immunotherapy for Chronic Hepatitis B Virus Infection. Gut and Liver, 12, 497-507. [Google Scholar] [CrossRef] [PubMed]
[10] Tang, C.-M., Yau, T.O. and Yu, J. (2014) Management of Chronic Hepatitis B Infection: Current Treatment Guidelines, Chal-lenges, and New Developments. World Journal of Gastroenterology, 20, 6262-6278. [Google Scholar] [CrossRef] [PubMed]
[11] Zhang, T.Y., Yuan, Q., Zhao, J.H., et al. (2016) Prolonged Sup-pression of HBV in Mice by a Novel Antibody That Targets a Unique Epitope on Hepatitis B Surface Antigen. Gut, 65, 658-671. [Google Scholar] [CrossRef] [PubMed]
[12] Seto, W.K., Chan, T.S.Y., Hwang, Y.Y., et al. (2014) Hepatitis B Reactivation in Patients with Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study. Journal of Clinical Oncology, 32, 3736-3743. [Google Scholar] [CrossRef] 
[13] Chang, K.M. and Liu, M. (2016) Chronic Hepatitis B: Immune Pathogenesis and Emerging Immunotherapeutics. Current Opinion in Pharmacology, 30, 93-105. [Google Scholar] [CrossRef] [PubMed]
[14] Claire, D., Dimitra, P., Pooja, K., et al. (2009) Temporal Analysis of Early Immune Responses in Patients with Acute Hepatitis B Virus Infection. Gastroenterology, 137, 1289-1300. [Google Scholar] [CrossRef] [PubMed]
[15] Luangsay, S., Gruffaz, M., Isorce, N., et al. (2015) Early Inhibi-tion of Hepatocyte Innate Responses by Hepatitis B Virus. Journal of Hepatology, 63, 1314-1322. [Google Scholar] [CrossRef] [PubMed]
[16] Ma, Z., Cao, Q., Xiong, Y., Zhang, E. and Lu, M. (2018) Interac-tion between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepa-titis B. Vaccines, 6, 6. [Google Scholar] [CrossRef] [PubMed]
[17] Lanford, R.E., Guerra, B., Chavez, D., et al. (2013) GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees. Gastroenterology, 144, 1508-1517.e10. [Google Scholar] [CrossRef] [PubMed]
[18] Li, L., Yue, P., Lanford, R., et al. (2014) The Antiviral Response to the Toll-Like Receptor 7 Agonist GS-9620 in Preclinical Models of Chronic Hepatitis B is Associated with an Intra-hepatic Cytotoxic T Cell Transcriptional Signature. 65th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 7-11 November 2014. http://www.natap.org/2014/AASLD/AASLD_140.htm
[19] Gane, E., Kim, H.J., Visvanathan, K., et al. (2018) Safety, Pharmacokinetics, and Pharmacodynamics of Oral TLR8 Agonist GS-9688 in Patients with Chronic Hepatitis B: A Randomized, Placebo-Controlled, Double-Blind Phase 1b Study. AASLD. http://www.natap.org/2018/AASLD/AASLD_236.htm
[20] Manzoor, S., Saalim, M., Imran, M., et al. (2015) Hepatitis B Virus Therapy: What’s the Future Holding for Us? World Journal of Gastroenterology, 21, 12558-12575. [Google Scholar] [CrossRef] [PubMed]
[21] Li, J., Ge, J., Ren, S., et al. (2015) Hepatitis B Surface Antigen (HBsAg) and Core Antigen (HBcAg) Combine CpG Oligodeoxynucletides as a Novel Therapeutic Vaccine for Chronic Hepatitis B Infection. Vaccine, 33, 4247-4254. [Google Scholar] [CrossRef] [PubMed]
[22] Chen, M., Li, Y.G., Zhang, D.Z., et al. (2005) Therapeutic Ef-fect of Autologous Dendritic Cell Vaccine on Patients with Chronic Hepatitis B: A Clinical Study. World Journal of Gastroenterology, 11, 1806-1808. [Google Scholar] [CrossRef] [PubMed]
[23] Akbar, S.M.F., Furukawa, S., Onji, M., et al. (2004) Safety and Ef-ficacy of Hepatitis B Surface Antigen-Pulsed Dendritic Cells in Human Volunteers. Hepatology Research, 29, 136-141. [Google Scholar] [CrossRef] [PubMed]
[24] Cao, H., Zhang, R. and Zhang, W. (2018) CTLA-4 Interferes with the HBV-Specific T Cell Immune Response (Review). International Journal of Molecular Medicine, 42, 703-712. [Google Scholar] [CrossRef] [PubMed]
[25] Cho, H., Kang, H., Lee, H.H. and Kim, C.W. (2017) Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis. International Journal of Molecular Sciences, 18, 1517. [Google Scholar] [CrossRef] [PubMed]
[26] Tzeng, H.T., Tsai, H.F., Liao, H.J., et al. (2012) PD-1 Blockage Re-verses Immune Dysfunction and Hepatitis B Viral Persistence in a Mouse Animal Model. PLoS ONE, 7, e39179. [Google Scholar] [CrossRef] [PubMed]
[27] Gane, E., Gaggar, A., Nguyen, A.H., et al. (2017) A Phase1 Study Evaluating Anti-PD-1 Treatment with or without GS-4774 in HBeAg Negative Chronic Hepatitis B Patients. Journal of Hepatology, 66, S26-S27. [Google Scholar] [CrossRef] 
[28] Krebs, K., Böttinger, N., Huang, L.-R., et al. (2013) T Cells Expressing A Chimeric Antigen Receptor That Binds Hepatitis B Virus Envelope Proteins Control Virus Replication in Mice. Gastroenterology, 145, 456-465. [Google Scholar] [CrossRef] [PubMed]
[29] Kruse, R.L., Shum, T., Tashiro, H., Barzi, M., et al. (2018) HBsAg-Redirected T Cells Exhibit Antiviral Activity in HBV-Infected Human Liver Chimeric Mice. Cytotherapy, 20, 697-705. [Google Scholar] [CrossRef] [PubMed]
[30] Qasim, W., Brunetto, M., Gehring, A., et al. (2015) Im-munotherapy of HCC Metastases with Autologous T Cell Receptor Redirected T Cells Targeting HBsAg in a Liver Transplant Patient. Journal of Hepatology, 62, 486-491. [Google Scholar] [CrossRef] [PubMed]
[31] Liao, Y., Tang, Z., Liu, K., et al. (1996) Preparation and Applica-tion of Anti-HBx/Anti-CD3 Bispecific Monoclonal Antibody (BsAb) Retargeting Effector Cells for Lysis of Human Hepatoma Xenografts in Nude Mice. Oncology Reports, 3, 637-644. [Google Scholar] [CrossRef] [PubMed]
[32] Kah, J., Koh, S., Volz, T., et al. (2017) Lymphocytes Transiently Expressing Virus-Specific T Cell Receptors Reduce Hepatitis B Virus Infection. Journal of Clinical Investigation, 127, 3177-3188. [Google Scholar] [CrossRef] 
[33] Maini, M.K., Boni, C., Ogg, G.S., et al. (1999) Direct ex Vivo Analysis of Hepatitis B Virus-Specific CD8+ T Cells Associated with the Control of Infection. Gastroenterology, 117, 1386-1396. [Google Scholar] [CrossRef] 
[34] Kosinska, A.D., Zhang, E., Johrden, L., et al. (2013) Com-bination of DNA Prime—Adenovirus Boost Immunization with Entecavir Elicits Sustained Control of Chronic Hepatitis B in the Woodchuck Model. PLoS Pathogens, 9, e1003391. [Google Scholar] [CrossRef] [PubMed]
[35] Li, J., Bao, M., Ge, J., et al. (2017) Research Progress of Therapeutic Vaccines for Treating Chronic Hepatitis B. Human Vaccines & Immunotherapeutics, 13, 986-997. [Google Scholar] [CrossRef] [PubMed]